What are the normal cerebrospinal fluid values and ratios for Alzheimer disease biomarkers such as amyloid beta 42 (Aβ42), amyloid beta 40 (Aβ40), the Aβ42/Aβ40 ratio, phosphorylated tau 181 (p‑tau181), the p‑tau181/Aβ42 ratio, and total tau?

Normal CSF Biomarker Values for Alzheimer's Disease

Based on current international guidelines and clinical practice, the following CSF biomarker thresholds are used to identify Alzheimer's disease pathology: Aβ42 ≤700 ng/L, Aβ42/Aβ40 ratio <0.06, p-tau181 ≥60 ng/L, and total tau ≥400 ng/L. 1, 2

Recommended Biomarker Cutoffs

Amyloid Biomarkers

• Aβ42: Pathological when ≤700 ng/L 1
• Aβ40: Pathological when >12,644 ng/L 2
• Aβ42/Aβ40 ratio: Pathological when <0.06 2
  • The Aβ42/Aβ40 ratio is preferred over Aβ42 alone when possible, as it provides superior diagnostic accuracy 3, 4

Tau Biomarkers

• Phosphorylated tau-181 (p-tau181): Pathological when ≥60 ng/L 1
• Total tau (t-tau): Pathological when ≥400 ng/L 1
• P-tau181/Aβ42 ratio: Values vary by assay platform but generally pathological when elevated 5

Diagnostic Framework

For definitive AD diagnosis, both amyloid AND tau biomarkers must be positive 3. This dual positivity requirement is critical because:

• Amyloid positivity alone occurs in other conditions (LATE, dementia with Lewy bodies, cerebral amyloid angiopathy)
• Tau positivity alone can occur in primary age-related tauopathy or atypical frontotemporal lobar degeneration

Interpretation Algorithm

When CSF results are clearly abnormal (all three markers pathological):

• Aβ42 ≤700 ng/L + p-tau181 ≥60 ng/L + t-tau ≥400 ng/L = High probability of AD 1

When results are discordant:

• Low Aβ42 but normal tau markers: AD still possible but less likely; consider adding Aβ40 measurement 1, 5
• Elevated tau but normal Aβ42: Consider other neurodegenerative disorders; measure Aβ40 to calculate Aβ42/Aβ40 ratio 1, 2

When Aβ42 alone is inconclusive:

• Adding Aβ40 measurement corrects interpretation in 76.2% of cases when using the Aβ42/Aβ40 ratio 2
• Using Aβ40 concentration alone corrects 94.7% of misclassified cases 2
• In patients with discordant p-tau181 and Aβ42 results, the Aβ42/Aβ40 ratio reduces indeterminate profiles by 50% 5

Critical Caveats

The Gray Zone Problem

Results within 10% of cutoff values represent an analytical gray zone with uncertain interpretation 1. In these cases:

• Repeat the CSF analysis
• Add imaging biomarkers (amyloid PET or tau PET)
• Consider clinical follow-up with repeat testing

Assay-Specific Considerations

The cutoff values provided are based on specific immunoassay platforms (primarily ELISA methods) 1. Different assay platforms may require different cutoffs, though the Aβ42/Aβ40 ratio shows better consistency across platforms than Aβ42 alone 4.

Age Effects

While not incorporated into standard cutoffs, plasma studies suggest Aβ42, Aβ40, and p-tau181 levels increase with age, while the Aβ42/Aβ40 ratio decreases with age 6. However, current CSF diagnostic thresholds do not adjust for age in clinical practice 1.

Superiority of the Aβ42/Aβ40 Ratio

The Aβ42/Aβ40 ratio demonstrates superior diagnostic performance compared to Aβ42 alone 3, 4:

• Better specificity for differentiating AD from vascular dementia, dementia with Lewy bodies, and frontotemporal dementia 7
• Higher accuracy for predicting amyloid PET positivity (AUC 0.90 vs 0.78 for Aβ42 alone) 4
• Reduces inter-individual variability in total brain amyloid load 7

The ratio performs comparably to the combination of Aβ42, p-tau181, and t-tau for differentiating AD from non-AD dementia 7, making it a simpler, more interpretable alternative.